(Albany, New York)- 2nd Sep 2026 – The market dynamics for Atopic Dermatitis are witnessing significant growth driven by rising disease prevalence, increasing diagnosis rates, growing awareness of the disease burden, and the expanding adoption of targeted systemic therapies. Additionally, the approval and growing use of therapies such as DUPIXENT (dupilumab), RINVOQ (upadacitinib), CIBINQO (abrocitinib), EBGLYSS (lebrikizumab), MITCHGA/NEMLUVIO (nemolizumab), and other emerging biologics and JAK inhibitors are expected to further propel the Atopic Dermatitis market during the forecast period.
DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Atopic Dermatitis Market Insights, Epidemiology and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Atopic Dermatitis, including historical and forecasted epidemiology, market trends, treatment scenarios, patient burden, and competitive landscape across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Atopic Dermatitis Market
The market size for Atopic Dermatitis in the leading markets is expected to grow significantly by 2036.
The 7MM Atopic Dermatitis market was approximately USD 13,000 million in 2025 and is projected to increase to nearly USD 28,000 million by 2036, reflecting a 7.0% CAGR during 2026–2036.
According to DelveInsight’s estimates, the total prevalent cases of Atopic Dermatitis in the 7MM were approximately 73,243,000 in 2025.
In 2025, there were approximately 33,120,000 diagnosed prevalent cases of Atopic Dermatitis in the United States, with the patient population projected to increase by 2036.
Atopic Dermatitis prevalence was higher among children younger than 18 years, accounting for approximately 35% compared with adults across the 7MM.
In 2025, mild Atopic Dermatitis was the most prevalent severity subtype in the United States, accounting for approximately 14,739,000 cases, followed by moderate Atopic Dermatitis.
Females accounted for a higher proportion of Atopic Dermatitis cases than males across the 7MM.
Approximately 25% of Atopic Dermatitis cases are either undiagnosed or misdiagnosed, highlighting a significant need for accurate and timely diagnosis.
The United States accounted for approximately USD 9,000 million of the Atopic Dermatitis market in 2025, making it the largest market across the 7MM.
DUPIXENT (dupilumab) generated the highest revenue among Atopic Dermatitis therapies in the United States in 2025.
Leading Atopic Dermatitis companies, including Roche, Eli Lilly and Company, Chugai Pharmaceutical, Galderma, Maruho, AbbVie, Pfizer, LEO Pharma, Otsuka Pharmaceutical, Incyte Corporation, Torii Pharmaceutical, Sanofi, Regeneron Pharmaceuticals, and others, are actively developing innovative therapies expected to transform the Atopic Dermatitis treatment landscape over the coming years.
Promising Atopic Dermatitis therapies in clinical development include Amlitelimab, Orismilast, Ucenprubart, Bosakitug, and others.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/atopic-dermatitis-market
Key Factors Driving the Atopic Dermatitis MarketRising Atopic Dermatitis Prevalence
The increasing prevalence of Atopic Dermatitis, particularly among younger populations and females, is a major driver of market expansion. In the United States, approximately 33,120,000 diagnosed prevalent cases were reported in 2025, with the patient pool projected to increase through 2036.
Expansion of Targeted Biologics and JAK Inhibitors
The Atopic Dermatitis treatment landscape has evolved significantly with the introduction of targeted biologics and oral JAK inhibitors. Therapies such as DUPIXENT, RINVOQ, CIBINQO, EBGLYSS, and ADBRY/ADTRALZA have expanded treatment options for patients with moderate-to-severe disease. The growing adoption of these targeted therapies is expected to support continued market expansion.
Increasing Demand for Pediatric and Age-Specific Therapies
With increasing diagnoses among younger populations, there is significant potential for therapies specifically tailored to children and adolescents, particularly treatments offering long-term safety and effective disease control. Broader pediatric indications and improved access to novel therapies are expected to contribute to market growth.
Robust Pipeline of Emerging Therapies
The Atopic Dermatitis pipeline continues to expand with therapies targeting novel immune pathways. Emerging treatments such as amlitelimab, an OX40L inhibitor, orismilast, a PDE4 inhibitor, and bosakitug, a TSLP inhibitor, are expected to diversify treatment options and address unmet needs among patients who do not respond adequately to existing therapies.
Atopic Dermatitis Competitive Landscape
The Atopic Dermatitis treatment landscape includes topical therapies, phototherapy, systemic immunosuppressants, biologics, and oral small-molecule therapies. Foundational treatment includes emollients, topical corticosteroids, topical calcineurin inhibitors, and PDE4 inhibitors, while systemic treatments are used for patients with moderate-to-severe disease or inadequate response to topical therapies.
DUPIXENT (dupilumab) has played a landmark role in transforming the treatment landscape since its approval in 2017. The therapy targets IL-4 and IL-13 signaling and is approved for adults and pediatric patients aged 6 months and older with moderate-to-severe Atopic Dermatitis whose disease is not adequately controlled with topical prescription therapies.
The competitive landscape has further expanded with RINVOQ (upadacitinib) and CIBINQO (abrocitinib), selective JAK1 inhibitors that provide rapid itch relief and skin clearance. Other approved therapies include EBGLYSS (lebrikizumab), an IL-13 inhibitor; MITCHGA/NEMLUVIO (nemolizumab), an IL-31 inhibitor; and ADBRY/ADTRALZA (tralokinumab), an IL-13 inhibitor.
The emerging pipeline is increasingly focused on novel immune targets. Amlitelimab (KY1005) targets OX40L, while Orismilast targets PDE4 and Bosakitug targets TSLP. These therapies are expected to further reshape the Atopic Dermatitis treatment landscape during the forecast period.
Discover more about therapies set to grab major Atopic Dermatitis market share @ Atopic Dermatitis Treatment Landscape
Recent Developments in the Atopic Dermatitis Market
In March 2026, Sanofi presented new results from its Phase III amlitelimab studies in Atopic Dermatitis during a late-breaking research session at the American Academy of Dermatology Annual Meeting 2026.
In March 2026, Eli Lilly announced positive Phase III results from the ADorable-1 trial for lebrikizumab in pediatric Atopic Dermatitis patients aged 6 months and older, demonstrating significant improvements in skin clearance and itch.
In January 2026, dermatology updates highlighted the continued expansion of novel therapies for Atopic Dermatitis, including newer topical and biologic agents, reflecting rapid innovation and broader treatment options across age groups.
In September 2025, the US Food and Drug Administration approved ruxolitinib cream (OPZELURA) for pediatric patients aged 2–11 years, expanding access to a topical JAK inhibitor for Atopic Dermatitis.
In March 2026, Kyowa Kirin announced the termination of all clinical trials for rocatinlimab.
What is Atopic Dermatitis?
Atopic Dermatitis, also known as eczema, is a chronic inflammatory skin condition characterized by itchiness, redness, irritation, and recurrent or persistent skin lesions. It commonly begins during childhood but can occur at any age and may continue throughout life.
Atopic Dermatitis is associated with genetic factors, immune system dysfunction, infections, allergies, and exposure to irritating substances. It is the most common chronic skin disease in children, and patients with moderate-to-severe disease may also experience comorbid conditions such as asthma, allergic rhinitis, and food allergies.
Diagnosis is primarily clinical because there is no specific laboratory test for Atopic Dermatitis. Diagnosis is based on characteristic features such as pruritus, chronic or relapsing eczematous lesions, typical distribution patterns, and a personal or family history of atopy, while excluding other conditions. Skin biopsy and microbiological testing may be used to rule out alternative or secondary conditions.
Treatment aims to reduce inflammation and pruritus, restore the skin barrier, prevent flares and infections, and improve quality of life. Management generally follows a stepwise approach involving emollients, topical corticosteroids, topical calcineurin inhibitors, PDE4 inhibitors, phototherapy, biologics, and systemic JAK inhibitors depending on disease severity and treatment response.
Atopic Dermatitis Epidemiology Segmentation
The Atopic Dermatitis epidemiology section provides insights into the historical and current Atopic Dermatitis patient pool and forecasted trends across the seven major markets. The Atopic Dermatitis market report provides epidemiological analysis for the study period 2022–2036, segmented into:
Total Prevalent Cases of Atopic Dermatitis
Total Prevalent Cases of Atopic Dermatitis by Age
Total Diagnosed Prevalent Cases of Atopic Dermatitis
Total Diagnosed Prevalent Cases of Atopic Dermatitis by Severity
Total Diagnosed Prevalent Cases of Atopic Dermatitis by Gender
Scope of the Atopic Dermatitis Market Report
Therapeutic Assessment: Current marketed and emerging therapies for Atopic Dermatitis
Atopic Dermatitis Market Dynamics: Key market forecast assumptions, pricing trends, therapy uptake, market share, and market outlook
Key Companies: Roche, Eli Lilly and Company, Chugai Pharmaceutical, Galderma, Maruho, AbbVie, Pfizer, LEO Pharma, Otsuka Pharmaceutical, Incyte Corporation, Torii Pharmaceutical, Sanofi, Regeneron Pharmaceuticals, and others
Key Therapies: Lebrikizumab (EBGLYSS), Nemolizumab (MITCHGA), Upadacitinib (RINVOQ), Abrocitinib (CIBINQO), Tralokinumab (ADBRY/ADTRALZA), Difamilast (MOIZERTO), Baricitinib (OLUMIANT), Dupilumab (DUPIXENT), Amlitelimab, Orismilast, Bempikibart, and others
Competitive Intelligence Analysis: SWOT Analysis and Conjoint Analysis
Unmet Needs, KOL’s Views, Analyst’s Views, Atopic Dermatitis Market Access and Reimbursement
To know more about Atopic Dermatitis companies working in the treatment market, visit @ Atopic Dermatitis Clinical Trials and Therapeutic Assessment
Table of Contents
Atopic Dermatitis Market Report Introduction
Executive Summary for Atopic Dermatitis
Key Events of Atopic Dermatitis
SWOT Analysis of Atopic Dermatitis
Atopic Dermatitis Patient Share (%) Overview at a Glance
Atopic Dermatitis Market Overview at a Glance
Atopic Dermatitis Background and Overview
Atopic Dermatitis Epidemiology and Patient Population
Country-Specific Patient Population of Atopic Dermatitis
Atopic Dermatitis Current Treatment and Medical Practices
Atopic Dermatitis Unmet Needs
Atopic Dermatitis Emerging Therapies
Atopic Dermatitis Market Outlook
Country-Wise Atopic Dermatitis Market Analysis (2022–2036)
Atopic Dermatitis Market Access and Reimbursement of Therapies
Atopic Dermatitis Market Drivers
Atopic Dermatitis Market Barriers
Atopic Dermatitis Appendix
Atopic Dermatitis Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
